பெஹ்ரிங் தடுப்பு மருந்துகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Synopsis “The company plans to produce 200 million doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based on inactivated vero cell platform technology, under stringent levels of GMP and biosafety,” the statement said. Production of Covaxin from this facility will commence from Q4 2021. Hyderabad-based Bharat Biotech said it has ramped up manufacturing capacity for Covaxin, its indigenous Covid-19 vaccine, by another 200 million doses a year using a facility in Gujarat currently operated by its wholly-owned subsidiary Chiron Behring Vaccines. Production of Covaxin from this facility will commence from Q4 2021. This effectively takes the Covaxin volume up to about 1 billion doses per annum, the company said in a statement on Thursday.

Uttar pradeshAndhra pradeshIndian immunologicalsBharat immunologicalsSupreme courtHaffkine biopharmaceutical corporationHyderabad based bharat biotechChiron behringBehring vaccinesBharat biotechCovid 19Vaccination driveஉத்தர் பிரதேஷ்ஆந்திரா பிரதேஷ்உச்ச நீதிமன்றம்ஹைதராபாத் அடிப்படையிலானது பாரத் பயோடெக்